Beximco Pharmaceuticals Ltd Notification of Preliminary Results and AGM (9407L)
October 07 2016 - 1:00AM
UK Regulatory
TIDMBXP
RNS Number : 9407L
Beximco Pharmaceuticals Ltd
07 October 2016
BEXIMCO PHARMACEUTICALS LTD.
7(th) October, 2016
Notification of Preliminary Results and Annual General
Meeting
Beximco Pharmaceuticals Ltd. (or "Company"; LSE-AIM: BXP) today
announces information for the shareholders of the Company that the
Board of Directors at their meeting held on 6(th) October 2016 has
decided the following:
1. Recommended Dividend : 5% final cash dividend
for the period of 18 i.e. Taka 0.50 per share,
months ended on 30(th) in addition to 10% interim
June, 2016 cash and 5% stock dividend
recommended by the Board
of Directors of the Company
on April 20, 2016 having
record date as May 12,
2016.
With 10% interim cash
dividend already paid,
the cumulative dividend
for the period amounts
to 15% cash and 5% stock.
------------------------- ------------------------- ------------ -----------------------------------
2. Record date : The Record date for entitlement
of 5% final cash dividend
will be November 1, 2016.
The Shareholders whose
names appear in the Share
Register of the Company
or in the Depository
Register on the record
date i.e. November 1,
2016 will be entitled
to receive the 5% final
cash dividend.
5% stock dividend will
be entitled by the shareholders
whose names appeared
in the Share Register
of the Company or in
the Depository Register
on the earlier declared
record date i.e. May
12, 2016.
------------------------- ------------------------- ------------ -----------------------------------
3. Date & Time of 40(th) : 19 November, 2016 at
AGM 10.30 AM
------------------------- ------------------------- ------------ -----------------------------------
4. Venue of 40(th) AGM : Beximco Industrial Park,
Sarabo,
Kashimpur, Gazipur.
------------------------- ------------------------- ------------ -----------------------------------
5. The Financial highlights for the 18 months period
ended on 30 June, 2016:
------------------------- ----------------------------------------------------------------------------
Jan 15- Jan 16- Jan 15 Jan 14-
Jun 16 Jun 16 - Dec 15 Dec 14
(18 months) (6 months) (12 months) (12 months)
-------------------------- ------------------------ ------------ ----------------- ----------------
Profit before
Tax (Taka in thousand) 3,657,838 1,320,708 2,337,130 2,109,556
-------------------------- ------------------------ ------------ ----------------- ----------------
Profit After Tax
(Taka in thousand) 2,948,054 993,769 1,954,285 1,528,298
-------------------------- ------------------------ ------------ ----------------- ----------------
Earnings Per Share
(Taka) 7.63 2.57 5.06 3.96
-------------------------- ------------------------ ------------ ----------------- ----------------
Net Asset Value As on Jun 30, 2016: Taka 59.70
per Share (NAV) As on Dec 31, 2014: Taka 56.87
-------------------------- ---------------------------------------------------------------------------
Net Operating For Jan 15 - Jun 16 (18 months)
Cash flow per : Taka 8.21
Share For Jan 14- Dec 14 (12 months)
: Taka 6.02
-------------------------- ---------------------------------------------------------------------------
For further information please visit www.beximco-pharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebulizer solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of Australia, Europe,
Latin America, Canada and the US, among others. The Company's
products are sold to retail outlets, medical institutions and other
pharmaceutical manufacturers in Bangladesh, in regional markets
such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and
in other markets overseas, principally in Africa, including South
Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific
Island; Latin and Central American countries; Middle East, Central
Asia, South East Asia, including Singapore, Malaysia, Indonesia,
Philippines and Hong Kong; Europe, Including Austria, Germany and
Romania and Austria and Australia.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUNVNRNOARRAA
(END) Dow Jones Newswires
October 07, 2016 02:00 ET (06:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024